Clinical Trial

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 22, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.
Trial Details
NCT Number NCT06786338
Lead Sponsor Suzhou Sanegene Bio Inc.
Conditions IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
Enrollment 38 participants
Start Date 2025-04-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-22